Results 1 to 10 of about 17,564 (161)
Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia [PDF]
Biology, 2023 Background. Patients with β-thalassemia have a high incidence of atrial fibrillation (AF) and other supraventricular arrhythmias. The use of non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prophylaxis in patients with β ...
Michele Malagù +8 more
doaj +2 more sources
Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [PDF]
The Korean Journal of Internal Medicine, 2023 In the last decade, non-vitamin K antagonist oral anticoagulants (NOACs), a new generation of OACs, were introduced to prevent thromboembolism in patients with atrial fibrillation.
Ki Hong Lee, Hyung Wook Park
doaj +2 more sources
Clinical Interventions in Aging, 2015 Mohit K Turagam, Poonam Velagapudi, Greg C FlakerDivision of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USAAbstract: Stroke prevention in elderly atrial fibrillation patients remains a challenge.
Turagam MK, Velagapudi P, Flaker GC
doaj +2 more sources
The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation [PDF]
Romanian Journal of Neurology, 2021 The prevalence of atrial fibrillation is lower in females than in men, but the risk of stroke and systemic thromboembolism is comparable or even higher. Administration of anticoagulant therapy does not modify this difference. Two classes of non-vitamin K
Despina-Manuela Toader +3 more
doaj +1 more source
Anatolian Journal of Cardiology, 2022 Background: The meta-analysis of randomized controlled trials has illustrated that the efficacy of low-dose non-vitamin K antagonist oral anticoagulants is inferior compared with standard-dose non-vitamin K antagonist oral anticoagulants, though they are
Zei Li +6 more
doaj +1 more source
Xiehe Yixue Zazhi, 2022 Oral anticoagulants can effectively reduce the risk of stroke in patients with atrial fibrillation. However, patients with atrial fibrillation and chronic renal insufficiency have an increased risk in both stroke and bleeding, making anticoagulant ...
LI Xin +5 more
doaj +1 more source
JRSM Open, 2021 Objective Several trials had compared the efficacy and safety between non-vitamin K antagonist oral anticoagulants and warfarin for acute venous thromboembolism, but the results were incomplete.
Yan Zhuang, Lin-feng Dai, Ming-qi Chen
doaj +1 more source
Український журнал серцево-судинної хірургії, 2023 Non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) are important pharmaceuticals for prevention of stroke and systemic embolism in non-valvular atrial fibrillation patients.
Larysa A. Vozniuk +2 more
doaj +1 more source
Emergency Care Journal, 2021 Closed chest traumas are frequent consequences of falls in the elderly. The presence of concomitant oral anticoagulant therapy can increase the risk of post-traumatic bleeding even in cases of trauma with non-severe dynamics. There is limited information
Gianni Turcato +9 more
doaj +1 more source
BMC Primary Care, 2022 Background To assess baseline characteristics, drug utilisation and healthcare use for oral anticoagulants (OACs) following the introduction of non-vitamin K antagonist oral anticoagulants among patients with atrial fibrillation in primary care in Norway.
Sigrun Halvorsen +6 more
doaj +1 more source